Premium
Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa
Author(s) -
Issell Brian F.,
Prout George R.,
Soloway Mark S.,
Cummings Kenneth B.,
Brannen George,
Veenema Ralph,
Flanagan Malachi,
Block Norman L.,
Summers Jack L.,
Levin Elizabeth A.,
Dianne Defuria M.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840301)53:5<1025::aid-cncr2820530502>3.0.co;2-d
Subject(s) - thiotepa , medicine , surgery , bladder cancer , mitomycin c , irritation , cancer , urology , chemotherapy , cyclophosphamide , immunology
Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty‐two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a Tl tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty‐five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose‐limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients. Cancer 53:1025‐1028, 1984.